medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2011, Number 2

<< Back

Residente 2011; 6 (2)

Endocanabinoides e inflamación

Cervantes VRD, González EC, Cruz MCSL

Language: Spanish
References: 30
Page: 127-135
PDF size: 101.89 Kb.


ABSTRACT

This paper focuses on the effects of endocannabinoids in inflammatory processes. It provides an overview of cannabinoids, their structure, main effects and mechanisms of action. General aspects of inflammatory processes, mediators involved, and the modulatory role of endocannabinoids in the inflammatory processes are reviewed along with possibilities for therapeutic intervention. Cannabinoids act on specific receptors coupled to Gi proteins. Arachidonoyl ethanolamide (AEA or anandamide) and 2-arachidonoyl glycerol (2-AG) are the endocannabinoids better characterized. These compounds are synthesized in response to calcium intracellular increase and diffuse from postsynaptic neurons to presynaptic neurons acting as retrograde messengers. Recently, endocannabinoids have been identified as compounds with potent anti-inflammatory actions, capable of inhibiting various stages of the processes in which the immune system controls infection and tissue damage. All these features have opened a scenario where the proper use of these compounds could improve the therapy for many chronic degenerative diseases.


REFERENCES

  1. Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. Br J Ophthalmol 2004; 88: 708-713.

  2. Onaivi ES, Sugiura T, Di Marzo. Endocannabinoids. The brain and body’s marijuana and beyond. Boca Raton FL, CRC Taylor and Francis Group 2006.

  3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.

  4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.

  5. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995; 232: 54-61.

  6. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Madelbaum A, Etinger A, Mecoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.

  7. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009; 89: 309-380.

  8. Howlett AC, Breivogel CS, Childers SR, Daedwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacol 2004; 47: 345-358.

  9. Bosier B, Muccioli GG, Hermans E, Lambert DM. Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 2010; 80: 1-12.

  10. Pertwee FG, Holette AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptor and their ligands: Beyond CB1 and CB2. Pharmacol Rev 2010; 62: 588-631.

  11. Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-837.

  12. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology, 6th Edition, Philadelphia, PA, USA, Saunders Elsevier, 2010.

  13. Serhan CN. Novel lipid mediators an resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 2010; 177: 1576-1591.

  14. Nathan C. Points of control in inflammation. Nature 2002; 420: 846-852.

  15. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413: 203-210.

  16. Nagarkatti P, Pandey R, Reider SA, Hedge VL, Nagarkatti M. Cannabinoids as a novel anti-inflammatory drugs. Fut Med Chem 2009; 1: 1333-1349.

  17. Zhu W, Friedman H, Klein TW. Delta 9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase 1. J Pharmacol Exp Ther 1998; 286: 1103-1109.

  18. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti, PS. Delta 9 tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther 2002; 302: 451-465.

  19. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. Activation through cannabinoid receptors 1 and 2 on dendritic cell triggers NFkB dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 2004; 173: 2373-2382.

  20. Mechoulam R, Panikashvilli D, Shohami E. Cannabinoids and brain injury: Therapeutic implications. Trends Mol Med 2002; 8: 58-61.

  21. Blanchard KD, Newton C, Klein TW, Stewart WE, Friedman H. In vitro and in vivo suppressive effects of delta-9-tetrahydrocannabinol on interferon production by murine spleen cells. Int J Immunopharmacol 1986; 8: 819-824.

  22. Smith SR, Terminelli C, Denhardt G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin 10 in endotoxemic mice. J Pharmacol Exp Ther 2000; 293: 136-150.

  23. Baldwin GC. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med 1997; 156: 1606-1613.

  24. Pacifici R. Modulation of the immune system in cannabis users. JAMA 2003; 289: 1929-1931.

  25. Klein TW. Cannabinoid receptors and T helper biasing. J Neuroimmunol 2003; 147: 91-94.

  26. Ni X. WIN 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 2004; 10: 158-164.

  27. Ibrahim MM. Activation of CB2 cannabinoid receptor by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci 2003; 100: 10529-10533.

  28. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized double blind placebo controlled crossover trial. BMJ 2004; 329: 253.

  29. Foulds J, Bruke M, Steinberg M, Williams JM, Ziedonis DM. Advances in pharmacotherapy for tobacco dependence. Exp Op Emerg Drugs 2004; 9: 39-53.

  30. Guzman M. Cannabinoids: potential anticancer agents. Nature Rev Cancer 2003; 3: 745-755.




2020     |     www.medigraphic.com